About 200 reports

Abstract: - Global Angina Pectoris Drugs Market to Reach $14.3 Billion by 2027 - Amid the COVID-19 crisis, the global market for Angina Pectoris Drugs estimated at US$10 Billion in the year 2020, is projected to reach a revised size of US$14.3 Billion by 2027, growing at a CAGR of 5.3% over the analysis period 2020-2027....

  • Angina
  • Calcium Channel Blocker
  • World
  • China
  • United States

Abstract: - Global Acute Heart Failure (AHF) Therapeutics Market to Reach $1.5 Billion by 2027 - Amid the COVID-19 crisis, the global market for Acute Heart Failure (AHF) Therapeutics estimated at US$372.9 Million in the year 2020, is projected to reach a revised size of US$1.5 Billion by 2027, growing at a CAGR of...

  • Therapy
  • Heart Failure
  • World
  • China
  • United States

Abstract: - Global Chronic Kidney Disease (CKD) Drugs Market to Reach $15.7 Billion by 2027 - Amid the COVID-19 crisis, the global market for Chronic Kidney Disease (CKD) Drugs estimated at US$13.7 Billion in the year 2020, is projected to reach a revised size of US$15.7 Billion by 2027, growing at a CAGR of 1.9% over...

  • Chronic Disease
  • World
  • China
  • United States

Chart ##: Calcium Channel Blocker Sales Volume and Market Share (Million yuan/Percent)

  • Hypertension
  • China
  • Industrial Production
  • Labour Force

The global ischemic heart disease (IHD) drugs market is expected to exhibit strong growth during 2021-2026. Ischemic heart disease (IHD), also known as coronary heart disease, is a condition that damages the heart muscle by interrupting the oxygen and blood supply. It involves molecular changes in the blood vessels...

  • Cardiovascular Disease
  • World

The global pulmonary arterial hypertension (PAH) drugs market reached a value of US$ 6.8 Billion in 2020. Looking forward, the analyst expects the market to grow at a CAGR of 7.3% during 2021-2026. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the...

  • Hypertension
  • World
  • Medical Technology Density

Abstract: - Global Scleroderma Diagnostics and Therapeutics Market to Reach $4 Billion by 2027 - Amid the COVID-19 crisis, the global market for Scleroderma Diagnostics and Therapeutics estimated at US$2 Billion in the year 2020, is projected to reach a revised size of US$4 Billion by 2027, growing at aCAGR of 10.3%...

  • Therapy
  • Dermatological Condition
  • Autoimmune Disease
  • Diagnostics
  • World
  • China
  • United States

Treatment includes sildenafil, prostanoids and calcium channel blockers.

  • Drug Development
  • Hypertension
  • South Africa
  • Drug Approval
  • Pharmaceutical Registrations

Treatment includes sildenafil, prostanoids and calcium channel blockers.

  • Hypertension
  • South Africa
  • Drug Approval
  • Cause-Specific Mortality Rate

Atherosclerosis Drugs Market – Scope of the Report This report on the global atherosclerosis drugs market studies the past as well as current growth trends and opportunities to gain valuable insights of the same indicators for the said market for the forecast period of 2019 to 2027.The report provides the overall market...

  • Cardiovascular Disease
  • World

KEY FINDINGS During the forecast period from 2019 to 2028, the global antihypertensive drugs market is estimated to grow with a CAGR of 3.21%. A surge in the prevalence of hypertension and a rise in awareness of complications related to hypertension, as well as an increase in the geriatric population and sedentary lifestyle,...

  • Hypertension
  • Antihypertensive
  • World
  • North America

Calcium Channel Blocker

  • Hypertension
  • China
  • Industrial Production
  • Labour Force

Treatment includes beta blockers, calcium channel blockers and blood thinners.

  • Cardiovascular Disease
  • Drug Development
  • World
  • Pharmaceutical Registrations
  • Interest Payments Paid By Central Government

Treatm ent includes beta bl ockers, calcium channel blockers and blood thinners.

  • Cardiovascular Disease
  • World
  • Pharmaceutical Registrations
  • Interest Payments Paid By Central Government

Table ##: Calcium Channel Blocker Sales Volume and Market Share by Drugs Classification in 2020 (Percent)

  • Hypertension
  • China
  • Employment Costs
  • Fuel Demand

Treatment includes beta blockers, calcium channel blockers and blood thinners.

  • Cardiovascular Disease
  • World
  • Pharmaceutical Registrations
  • Interest Payments Paid By Central Government

Pulmonary Arterial Hypertension - Pipeline Review, H2 2020 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Pulmonary Arterial Hypertension - Pipeline Review, H2 2020, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape. Pulmonary...

  • Hypertension
  • World
  • United States
  • North America
  • Drug Approval
  • Pharmaceutical Registrations

World Cardiovascular Drug Calcium Channel Blocker Therapy

  • Eating Disorder
  • Drug Development
  • World
  • Drug Approval
  • Dropout Rate

World Calcium Channel Blocker In Vitro Diagnostic Reagent

  • Neurological Disorder
  • World
  • Diagnostic Imaging Density
  • Dropout Rate

World Calcium Channel Blocker Cardiovascular Drug Hormone

  • Eating Disorder
  • World
  • Drug Approval
  • Dropout Rate

The other segment refers to beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents (ESAs).

  • Renal Disease
  • Central America
  • Brazil
  • Argentina
  • Patients Undergoing Dialysis
  • Health Expenditure

The other segment refers to beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents (ESAs).

  • Renal Disease
  • APAC
  • Patients Undergoing Dialysis
  • Health Expenditure

The other segment refers to beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents (ESAs).

  • Renal Disease
  • Europe
  • Health Expenditure
  • Mortality Rate

The other segment refers to beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents (ESAs).

  • Renal Disease
  • North America
  • Drug Approval
  • Final Consumption Expenditures

World Calcium Channel Blocker Hormone

  • Therapy
  • Cardiovascular Disease
  • Pharmaceutical
  • World
  • Health Provider Density
  • Dropout Rate

World Calcium Channel Blocker In Vitro Diagnostic Reagent

  • Neurological Disorder
  • Therapy
  • World
  • Diagnostic Imaging Density
  • Dropout Rate

The other segment refers to beta-blockers, calcium channel blockers, and erythropoiesis-stimulating agents (ESAs).

  • Renal Disease
  • Middle East
  • Africa
  • Diabetes Prevalence
  • Overweight Prevalence

World Calcium Channel Blocker Cardiovascular Drug

  • Ear Disease
  • Drug Development
  • World
  • Drug Approval

World Calcium Channel Blocker Analgesic

  • Neurological Disorder
  • Neurology
  • Pharmaceutical
  • World
  • Ghana
  • Drug Approval
  • Health Provider Density

World Calcium Channel Blocker Cardiovascular Drug Hormone

  • Eating Disorder
  • World
  • Drug Approval
  • Dropout Rate